<DOC>
	<DOCNO>NCT00171080</DOCNO>
	<brief_summary>The purpose study compare efficacy , safety tolerability valsartan 80 mg ( start dose 40 mg ) irbesartan 150 mg ( start dose 75 mg ) patient long-term haemodialysis mild moderate increase mean supine systolic blood pressure ( MSSBP ) .</brief_summary>
	<brief_title>VALID : Study Compare Reduction Predialysis Systolic Blood Pressure With Valsartan Compared Irbesartan Patients With Mild Moderate Hypertension Long-term Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Patients mild moderate hypertension define MSSBP ≥ 140 mmHG &lt; 180 mmHG Visits 1 2 treat untreated patient Chronic hemodialysis least 6 month prior Visit 1 substitution therapy . If treat epoetin : patient stable hematocrit ≤ 40 % ( ± 5 % ) . Inability discontinue angiotensin II receptor blocker ( ARBs ) safely period 1 week , require protocol . Treatment 3 different compound treatment hypertension Visit 1 . Atrial fibrillation Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Valsartan</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Renal Disease</keyword>
</DOC>